US5149797A
(en)
*
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US20070032446A1
(en)
*
|
1991-12-24 |
2007-02-08 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5523389A
(en)
*
|
1992-09-29 |
1996-06-04 |
Isis Pharmaceuticals, Inc. |
Inhibitors of human immunodeficiency virus
|
EP1897942A1
(en)
*
|
1993-05-11 |
2008-03-12 |
The University Of North Carolina At Chapel Hill |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
US6410322B1
(en)
*
|
1993-07-27 |
2002-06-25 |
Hybridon Inc |
Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
|
US6605708B1
(en)
|
1993-07-28 |
2003-08-12 |
Hybridon, Inc. |
Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
|
ATE247128T1
(en)
|
1993-09-03 |
2003-08-15 |
Isis Pharmaceuticals Inc |
AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
|
AU8102694A
(en)
*
|
1993-11-17 |
1995-06-06 |
Id Biomedical Corporation |
Cycling probe cleavage detection of nucleic acid sequences
|
US5550047A
(en)
*
|
1994-02-18 |
1996-08-27 |
University Of Massachusetts |
Oligonucleotides with anti-Epstein-Barr virus activity
|
US5801235A
(en)
*
|
1994-05-25 |
1998-09-01 |
Hybridon, Inc. |
Oligonucleotides with anti-cytomegalovirus activity
|
US5691316A
(en)
*
|
1994-06-01 |
1997-11-25 |
Hybridon, Inc. |
Cyclodextrin cellular delivery system for oligonucleotides
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US5591721A
(en)
*
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US6608035B1
(en)
*
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US6509149B2
(en)
*
|
1995-06-06 |
2003-01-21 |
Hybridon, Inc. |
HPV-specific oligonucleotides
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US20030055240A1
(en)
*
|
1995-06-06 |
2003-03-20 |
Roberts Peter C. |
HPV specific oligonucleotides
|
JP4293636B2
(en)
|
1996-02-14 |
2009-07-08 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
Oligonucleotide with sugar-modified gap
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US5856462A
(en)
*
|
1996-09-10 |
1999-01-05 |
Hybridon Incorporated |
Oligonucleotides having modified CpG dinucleosides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
WO1999001579A1
(en)
|
1997-07-01 |
1999-01-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US6013786A
(en)
*
|
1997-08-22 |
2000-01-11 |
Hybridon, Inc. |
MDM2-specific antisense oligonucleotides
|
US20030036516A1
(en)
*
|
1997-09-10 |
2003-02-20 |
Sudhir Agrawal |
Method for using oligonucleotides having modified cpg dinucleotides
|
US6306831B1
(en)
|
1997-09-12 |
2001-10-23 |
Qik Technologies, Inc. |
Transplacental delivery of oligonucleotides
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6841539B1
(en)
|
1998-05-21 |
2005-01-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
EP1080103A4
(en)
|
1998-05-21 |
2003-07-02 |
Isis Pharmaceuticals Inc |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US5962672A
(en)
*
|
1998-09-18 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of RhoB expression
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
JP2003523166A
(en)
|
1998-09-29 |
2003-08-05 |
ガミダ セル リミテッド |
Methods for controlling proliferation and differentiation of stem and progenitor cells
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
JP2002539833A
(en)
|
1999-03-31 |
2002-11-26 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
Isolated DNAs encoding kalin regulators ROC1 and ROC2, isolated proteins encoded by them, and uses thereof
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
US20030078216A1
(en)
*
|
1999-05-03 |
2003-04-24 |
Macleod A. Robert |
Inhibition of histone deactylase
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US7101989B1
(en)
|
1999-07-09 |
2006-09-05 |
University Of North Carolina At Chapel Hill |
DsrA protein and polynucleotides encoding the same
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
US20010011126A1
(en)
*
|
1999-09-10 |
2001-08-02 |
Bock Elisabeth Marianne |
Neurogenic compositions and methods
|
US7332275B2
(en)
|
1999-10-13 |
2008-02-19 |
Sequenom, Inc. |
Methods for detecting methylated nucleotides
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
JP2004533850A
(en)
|
2000-03-24 |
2004-11-11 |
メチルジーン・インコーポレーテッド |
Inhibition of specific histone deacetylase isoforms
|
US20060052319A9
(en)
*
|
2000-04-03 |
2006-03-09 |
Sudhir Agrawal |
Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
CA2411139A1
(en)
*
|
2000-06-08 |
2001-12-13 |
James T. Willerson |
Inhibitors of c-reactive protein induced inflammation
|
US6958214B2
(en)
*
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
US6596490B2
(en)
*
|
2000-07-14 |
2003-07-22 |
Applied Gene Technologies, Inc. |
Nucleic acid hairpin probes and uses thereof
|
US6380377B1
(en)
*
|
2000-07-14 |
2002-04-30 |
Applied Gene Technologies, Inc. |
Nucleic acid hairpin probes and uses thereof
|
US20030152557A1
(en)
*
|
2001-01-12 |
2003-08-14 |
Besterman Jeffrey M. |
Methods for inhibiting histone deacetylase-4
|
US20030148970A1
(en)
*
|
2001-01-12 |
2003-08-07 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-4
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303262A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
CA2446606A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Methylgene, Inc. |
Inhibitors of dna methyltransferase isoforms
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
MXPA03011985A
(en)
|
2001-06-20 |
2004-03-26 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor.
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
SE0102327D0
(en)
|
2001-06-28 |
2001-06-28 |
Active Biotech Ab |
A novel engineered superantigen for human therapy
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US20040266718A1
(en)
*
|
2001-08-06 |
2004-12-30 |
Zuomei Li |
Inhibition of specific histone deacetylase isoforms
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US7868204B2
(en)
*
|
2001-09-14 |
2011-01-11 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
US6897220B2
(en)
*
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
CN1578663B
(en)
*
|
2001-09-14 |
2011-05-25 |
梅特希尔基因公司 |
Inhibitors of histone deacetylase
|
ES2390531T3
(en)
|
2001-09-18 |
2012-11-13 |
Genentech, Inc. |
Compositions and procedures for the diagnosis and treatment of tumor
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
EP1488233A4
(en)
|
2001-10-09 |
2006-06-21 |
Genentech Inc |
Novel acidic mammalian proteins and polynucleotides encoding the same
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
EP1465982A4
(en)
*
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
US7432342B2
(en)
|
2002-05-03 |
2008-10-07 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof and related documents
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
WO2003106617A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Tel Aviv Medical Center Research Development Fund |
Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
|
US20040072770A1
(en)
*
|
2002-07-03 |
2004-04-15 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-7 and 8
|
US20040009483A1
(en)
*
|
2002-07-12 |
2004-01-15 |
Ilsley Diane D. |
Method of linear mRNA amplification using total RNA
|
WO2004014314A2
(en)
|
2002-08-12 |
2004-02-19 |
David Kirn |
Methods and compositions concerning poxviruses and cancer
|
AU2003263853A1
(en)
*
|
2002-08-16 |
2004-03-03 |
Board Of Regents The University Of Texas System |
Compositions and methods related to flavivirus envelope protein domain iii antigens
|
JP2005538186A
(en)
*
|
2002-09-13 |
2005-12-15 |
レプリコール インコーポレーティッド |
Non-sequence complementary antiviral oligonucleotides
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
DK1545587T3
(en)
|
2002-09-16 |
2011-05-09 |
Agennix Inc |
Lactoferrin compositions and methods for the treatment of diabetic wounds
|
EP1549767A4
(en)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation of forkhead box o1a expression
|
US20040137472A1
(en)
*
|
2002-09-27 |
2004-07-15 |
Ryszard Kole |
Methods and compositions for modification of splicing of pre-mRNA
|
CA2501265A1
(en)
*
|
2002-10-17 |
2004-04-29 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
EP1560839A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimeric oligomeric compounds and their use in gene modulation
|
EP1578765A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
EP1569695B1
(en)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
DK2336318T3
(en)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
|
WO2004046330A2
(en)
|
2002-11-15 |
2004-06-03 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
AU2004206820B2
(en)
*
|
2003-01-16 |
2010-06-10 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
CA2515484C
(en)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
AU2004220556B2
(en)
|
2003-03-07 |
2009-05-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
JP2007524380A
(en)
|
2003-04-02 |
2007-08-30 |
ボード オブ リージェンツ ザ ユニバーティー オブ テキサス システム |
Bik mutant with antitumor effect
|
AU2004229519B2
(en)
|
2003-04-09 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
iRNA conjugates
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP1625138A4
(en)
|
2003-04-17 |
2010-06-23 |
Alnylam Pharmaceuticals Inc |
Protected monomers
|
EP2664672A1
(en)
|
2003-04-17 |
2013-11-20 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US7569554B2
(en)
*
|
2003-05-16 |
2009-08-04 |
Idera Pharmaceuticals, Inc. |
Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
KR101137572B1
(en)
|
2003-06-11 |
2012-05-30 |
이데라 파마슈티칼즈, 인코포레이티드 |
Stabilized immunomodulatory oligonucleotides
|
WO2004113496A2
(en)
*
|
2003-06-20 |
2004-12-29 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
|
MXPA06000619A
(en)
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy.
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
EP2182063A3
(en)
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation of EIF4E expression
|
AU2004274021B2
(en)
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
AU2004276337B2
(en)
*
|
2003-09-24 |
2009-11-12 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
EP1687410A4
(en)
*
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
Antisense oligonucleotides optimized for kidney targeting
|
EP1678194B1
(en)
|
2003-10-10 |
2013-06-26 |
Alchemia Oncology Pty Limited |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
EP2267154A1
(en)
|
2003-10-23 |
2010-12-29 |
Illumigen Biosciences, Inc. |
Oligoadenylate synthetase
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
JP4901478B2
(en)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
Compositions and methods for the treatment of tumors of hematopoietic origin
|
US20050120397A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hermann Steller |
Compounds and methods for regulation of spermatid differentiation
|
AU2004304770B2
(en)
*
|
2003-12-08 |
2010-05-06 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
US7741070B2
(en)
*
|
2003-12-24 |
2010-06-22 |
Massachusetts Institute Of Technology |
Gene targets for enhanced carotenoid production
|
WO2005062923A2
(en)
*
|
2003-12-24 |
2005-07-14 |
Massachusetts Institute Of Technology |
Gene targets for enhanced carotenoid production
|
US7608699B2
(en)
*
|
2003-12-29 |
2009-10-27 |
Rockefeller University |
Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
|
EP1711606A2
(en)
|
2004-01-20 |
2006-10-18 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
JP2007523173A
(en)
*
|
2004-02-20 |
2007-08-16 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Strong mucosal immune response induced by modified immunomodulatory oligonucleotides
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
US7253204B2
(en)
*
|
2004-03-26 |
2007-08-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
WO2005094370A2
(en)
*
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7427405B2
(en)
*
|
2004-06-15 |
2008-09-23 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory oligonucleotide multimers
|
WO2006002038A2
(en)
*
|
2004-06-15 |
2006-01-05 |
Hybridon, Inc. |
Immunostimulatory oligonucleotide multimers
|
US7785843B2
(en)
*
|
2004-06-23 |
2010-08-31 |
Sequenom, Inc. |
Target-specific compomers and methods of use
|
SI2206781T1
(en)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
US8680062B2
(en)
|
2004-07-06 |
2014-03-25 |
Deliversir Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
EP2990410A1
(en)
|
2004-08-10 |
2016-03-02 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
DK2997980T3
(en)
|
2004-08-10 |
2018-03-26 |
Kastle Therapeutics Llc |
PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1799812A4
(en)
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
WO2006034348A2
(en)
|
2004-09-17 |
2006-03-30 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
CA2584614A1
(en)
|
2004-10-20 |
2006-08-24 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin .alpha.4 expression
|
US8003619B2
(en)
*
|
2004-12-09 |
2011-08-23 |
Alnylam Pharmaceuticals, Inc. |
Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
|
CN101175769A
(en)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
Methods and compositions for modulating vascular integrity
|
WO2006102760A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
WO2006113666A2
(en)
*
|
2005-04-19 |
2006-10-26 |
Massachusetts Institute Of Technology |
Amphiphilic polymers and methods of use thereof
|
WO2007008300A2
(en)
|
2005-05-31 |
2007-01-18 |
ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
DK2380584T3
(en)
|
2005-07-01 |
2014-01-20 |
Index Pharmaceuticals Ab |
IMMUNSTIMULATING PROCEDURE
|
SI2179737T1
(en)
|
2005-07-01 |
2014-02-28 |
Index Pharmaceuticals Ab |
Modulating responsiveness to steroids
|
US20070026012A1
(en)
|
2005-08-01 |
2007-02-01 |
Cornell Research Foundation, Inc. |
Compositions and methods for monitoring and altering protein folding and solubility
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
WO2007030668A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
JP2009513629A
(en)
*
|
2005-10-28 |
2009-04-02 |
インデックス・ファーマシューティカルズ・アクチエボラーグ |
Compositions and methods for preventing, treating and / or alleviating inflammatory diseases
|
US7470674B2
(en)
*
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
AU2005338035B2
(en)
|
2005-11-07 |
2012-06-07 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
US7776834B2
(en)
*
|
2005-11-07 |
2010-08-17 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
JP2009516710A
(en)
|
2005-11-21 |
2009-04-23 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Modulating the expression of eIF4E-BP2
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
CN101379195B
(en)
*
|
2005-12-20 |
2012-05-09 |
艾德拉药物股份有限公司 |
Immunostimulatory activity of palindromic immune modulatory oligonucleotides (IMO tm) contiaining different lengths of palindromic segments
|
AU2006336242A1
(en)
*
|
2005-12-20 |
2007-07-26 |
Idera Pharmaceuticals, Inc. |
Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
|
WO2007123579A2
(en)
|
2005-12-28 |
2007-11-01 |
Translational Therapeutics |
Translational dysfunction based therapeutics
|
CN101437933B
(en)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
Natural antisense and non-coding RNA transcripts as drug targets
|
PT2161038E
(en)
|
2006-01-26 |
2014-03-10 |
Isis Pharmaceuticals Inc |
Compositions and their uses directed to huntingtin
|
EP2314594B1
(en)
*
|
2006-01-27 |
2014-07-23 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
US8129515B2
(en)
|
2006-01-27 |
2012-03-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
ES2452820T3
(en)
|
2006-04-07 |
2014-04-02 |
Methylgene, Inc. |
Benzamide derivatives as histone deacetylase inhibitors
|
US20090326041A1
(en)
|
2006-05-05 |
2009-12-31 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
DK2066684T3
(en)
|
2006-05-11 |
2012-10-22 |
Isis Pharmaceuticals Inc |
5'-Modified Bicyclic Nucleic Acid Analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
US9506056B2
(en)
|
2006-06-08 |
2016-11-29 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
LT2056845T
(en)
|
2006-08-08 |
2017-11-27 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5` phosphate oligonucleotides
|
EP1920775B1
(en)
|
2006-10-10 |
2012-12-19 |
Gunther Prof. Dr. Hartmann |
5'Triphosphate oligonucleotide induces anti-viral response
|
AU2007294858B2
(en)
|
2006-09-14 |
2011-05-12 |
Medgenics Medical Israel, Ltd |
Long lasting drug formulations
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
CA2921063C
(en)
|
2006-09-15 |
2020-01-28 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
CA2666968A1
(en)
|
2006-10-20 |
2008-10-30 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Modified cyanobacteria
|
DK2343286T3
(en)
|
2006-10-28 |
2015-04-13 |
Methylgene Inc |
Dibenzo [b, f] [1,4] oxazepine derivatives as inhibitors of histone deacetylase
|
US7645578B2
(en)
*
|
2006-10-31 |
2010-01-12 |
Agilent Technologies, Inc. |
Cleavage of RNA at redundant sites
|
EP2573069A3
(en)
|
2006-12-19 |
2013-05-22 |
MethylGene Inc. |
Inhibitors of histone deacetylase and prodrugs thereof
|
EP1935428A1
(en)
*
|
2006-12-22 |
2008-06-25 |
Antisense Pharma GmbH |
Oligonucleotide-polymer conjugates
|
WO2008094945A2
(en)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2121987B1
(en)
|
2007-02-09 |
2012-06-13 |
Northwestern University |
Particles for detecting intracellular targets
|
US8030344B2
(en)
*
|
2007-03-13 |
2011-10-04 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
PT2144633E
(en)
*
|
2007-04-23 |
2014-10-27 |
Deliversir Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
US9156865B2
(en)
|
2007-04-23 |
2015-10-13 |
Deliversir Ltd |
System for delivering therapeutic agents into living cells and cells nuclei
|
US9556210B2
(en)
|
2007-04-23 |
2017-01-31 |
Sabag-Rfa Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
AU2008260277C1
(en)
|
2007-05-30 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
DK2173760T4
(en)
|
2007-06-08 |
2016-02-08 |
Isis Pharmaceuticals Inc |
Carbocyclic bicyclic nukleinsyreanaloge
|
ES2376507T5
(en)
*
|
2007-07-05 |
2015-08-31 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
EP2188298B1
(en)
|
2007-08-15 |
2013-09-18 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009039442A1
(en)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
CA2700953A1
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
US20100280098A1
(en)
*
|
2007-10-05 |
2010-11-04 |
Juliano Rudolph L |
Receptor targeted oligonucleotides
|
WO2009064920A2
(en)
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2222851B1
(en)
|
2007-11-20 |
2017-06-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of cd40 expression
|
WO2009067647A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
US8426378B2
(en)
*
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
DK2285819T3
(en)
*
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS INCLUDING NEUTRAL BONDED, TERMINAL BICYCLIC NUCLEOSIDES
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
WO2010017248A2
(en)
|
2008-08-04 |
2010-02-11 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
JP2012513953A
(en)
|
2008-09-23 |
2012-06-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
Chemical modification of monomers and oligonucleotides using cycloaddition
|
US8501805B2
(en)
*
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
EP2361256B1
(en)
*
|
2008-09-24 |
2013-04-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acid analogs
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
WO2010048586A1
(en)
|
2008-10-24 |
2010-04-29 |
Avi Biopharma, Inc. |
Multiple exon skipping compositions for dmd
|
KR20220150995A
(en)
|
2008-11-10 |
2022-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
Novel lipids and compositions for the delivery of therapeutics
|
DK2365803T3
(en)
|
2008-11-24 |
2018-01-22 |
Univ Northwestern |
POLYVALENT RNA NANOPARTICLE COMPOSITIONS
|
ES2637063T3
(en)
|
2008-12-04 |
2017-10-10 |
Curna, Inc. |
Treatment of diseases related to tumor suppressor genes by inhibiting the natural antisense transcript to the gene
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
MX366774B
(en)
|
2008-12-04 |
2019-07-24 |
Curna Inc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1.
|
CA2746508A1
(en)
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
KR101546673B1
(en)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
Toner for electrophotographic and process for preparing the same
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP2393825A2
(en)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
PL2396038T3
(en)
|
2009-02-12 |
2016-05-31 |
Curna Inc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US20110319476A1
(en)
|
2009-02-12 |
2011-12-29 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
EP2403946A4
(en)
|
2009-03-04 |
2012-11-14 |
|
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
US8318690B2
(en)
|
2009-05-01 |
2012-11-27 |
Curna, Inc. |
Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
|
CN106237345A
(en)
|
2009-05-06 |
2016-12-21 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
ES2609655T3
(en)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
|
JP5922017B2
(en)
|
2009-05-18 |
2016-05-24 |
クルナ・インコーポレーテッド |
Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
EP2435571B1
(en)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
CN104873464B
(en)
|
2009-06-10 |
2018-06-22 |
阿布特斯生物制药公司 |
Improved lipid formulations
|
ES2629339T3
(en)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
|
KR101801404B1
(en)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
KR101807324B1
(en)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
KR101892760B1
(en)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
ES2538347T3
(en)
|
2009-08-27 |
2015-06-19 |
Idera Pharmaceuticals, Inc. |
Compositions to inhibit genetic expression and uses thereof
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
EP3409119B1
(en)
|
2009-09-14 |
2020-08-12 |
SillaJen Biotherapeutics, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
RU2539772C2
(en)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Methods and compositions for hepsin modulation of macrophage-stimulating protein
|
AU2010313154B2
(en)
|
2009-10-30 |
2016-05-12 |
Northwestern University |
Templated nanoconjugates
|
KR102487132B1
(en)
|
2009-11-12 |
2023-01-10 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
Antisense Molecules and Methods for Treating Pathologies
|
CN102712928B
(en)
|
2009-11-13 |
2017-08-04 |
萨雷普塔治疗公司 |
Antisense antiviral compound and the method for treating influenza infection
|
PE20121584A1
(en)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
MX337062B
(en)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Oncolytic rhabdovirus.
|
ES2661813T3
(en)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
RU2615450C2
(en)
|
2009-12-29 |
2017-04-04 |
Курна, Инк. |
Treating diseases associated with nuclear respiratory factor 1 (nrf1) by inhibition of natural antisense transcript to nrf1
|
JP5982288B2
(en)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
JP5963680B2
(en)
|
2010-01-06 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011085347A2
(en)
|
2010-01-11 |
2011-07-14 |
Opko Curna, Llc |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
ES2671877T3
(en)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
CN102844435B
(en)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
KR20130004579A
(en)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
EP2544703A4
(en)
|
2010-03-12 |
2013-09-18 |
Brigham & Womens Hospital |
Methods of treating vascular inflammatory disorders
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP2556160A4
(en)
|
2010-04-09 |
2013-08-21 |
Curna Inc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011139714A2
(en)
|
2010-04-26 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
CN103096911B
(en)
|
2010-04-27 |
2018-05-29 |
Atyr 医药公司 |
Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
EP2625186B1
(en)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
CN103154014B
(en)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
Modified nucleosides, modified nucleosides-like and oligomeric compounds prepared therefrom
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
WO2011150279A2
(en)
|
2010-05-27 |
2011-12-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
AU2011248457B2
(en)
|
2010-04-29 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
|
ES2625689T3
(en)
|
2010-04-29 |
2017-07-20 |
Ionis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
CN103097523B
(en)
|
2010-04-29 |
2016-09-28 |
Atyr医药公司 |
The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
CN107090045A
(en)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
Composition and method for tumor diagnosis and therapy
|
CN105820252B
(en)
|
2010-05-03 |
2020-07-21 |
Atyr 医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl- α -tRNA synthetases
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
US8961961B2
(en)
|
2010-05-03 |
2015-02-24 |
a Tyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
|
US8981045B2
(en)
|
2010-05-03 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
|
CA2798139C
(en)
|
2010-05-04 |
2019-09-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
US9457079B2
(en)
|
2010-05-12 |
2016-10-04 |
The Trustees Of Columbia University In The City Of New York |
Methods for producing enteroendocrine cells that make and secrete insulin
|
ES2816898T3
(en)
|
2010-05-13 |
2021-04-06 |
Sarepta Therapeutics Inc |
Compounds that modulate the signaling activity of interleukins 17 and 23
|
CN103200953B
(en)
|
2010-05-14 |
2017-02-15 |
Atyr 医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
TWI586356B
(en)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
AU2011256366C1
(en)
|
2010-05-17 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
KR20180053419A
(en)
|
2010-05-26 |
2018-05-21 |
큐알엔에이, 인크. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
JP2013532152A
(en)
|
2010-06-15 |
2013-08-15 |
メドジェニクス・メディカル・イスラエル・リミテッド |
Long-lasting pharmaceutical formulation
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
WO2012009402A2
(en)
|
2010-07-14 |
2012-01-19 |
Opko Curna Llc |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
CN103108650A
(en)
|
2010-08-25 |
2013-05-15 |
Atyr医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
|
EP3118316A1
(en)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
EP2630241B1
(en)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
ES2677070T3
(en)
|
2010-10-27 |
2018-07-27 |
Curna, Inc. |
Treatment of diseases related to the developmental regulator 1 associated with interferon (ifrd1) by inhibition of the natural antisense transcript to the ifrd1 gene
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
EP2640853B1
(en)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
ES2657590T3
(en)
|
2010-11-23 |
2018-03-06 |
Curna, Inc. |
Treatment of nanog related diseases by inhibiting the natural antisense transcript to nanog
|
WO2012094386A1
(en)
|
2011-01-04 |
2012-07-12 |
Jennerex Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
WO2012101601A1
(en)
|
2011-01-27 |
2012-08-02 |
Ramot At Tel-Aviv University Ltd. |
Glycogen synthase kinase-3 inhibitors
|
WO2012101599A2
(en)
|
2011-01-27 |
2012-08-02 |
Ramot At Tel-Aviv University Ltd. |
Glycogen synthase kinase-3 inhibitors
|
TWI593416B
(en)
|
2011-02-02 |
2017-08-01 |
艾克厘德製藥公司 |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
US20130338178A1
(en)
|
2011-02-02 |
2013-12-19 |
The Trustees Of Princeton University |
Sirtuin modulators as inhibitors of cytomegalovirus
|
US8877722B2
(en)
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
WO2012138223A2
(en)
|
2011-04-05 |
2012-10-11 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Compounds and methods for altering activin receptor-like kinase signalling
|
ES2627529T3
(en)
|
2011-06-08 |
2017-07-28 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
RU2620980C2
(en)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
US10202599B2
(en)
|
2011-08-11 |
2019-02-12 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
CA2847698C
(en)
|
2011-09-14 |
2020-09-01 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
JP6129844B2
(en)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
Multimeric oligonucleotide compounds
|
WO2013043720A1
(en)
|
2011-09-20 |
2013-03-28 |
The University Of North Carolina At Chapel Hill |
Regulation of sodium channels by plunc proteins
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
BR112014008925A2
(en)
|
2011-10-11 |
2020-10-27 |
The Brigham And Women's Hospital, Inc. |
micro rnas in neurodegenerative disorders
|
EP2596806A1
(en)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Method for prevention of colectomy
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
CA2863795A1
(en)
|
2012-02-13 |
2013-08-22 |
Gamida-Cell Ltd. |
Culturing of mesenchymal stem cells
|
CA2866819C
(en)
|
2012-03-13 |
2022-01-04 |
James Cook University |
Method for treating inflammation
|
EP2639238A1
(en)
|
2012-03-15 |
2013-09-18 |
Universität Bern |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
EP2831231A1
(en)
|
2012-03-30 |
2015-02-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
CN104704122A
(en)
|
2012-04-20 |
2015-06-10 |
艾珀特玛治疗公司 |
miRNA modulators of thermogenesis
|
CA2873809A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
US10059941B2
(en)
|
2012-05-16 |
2018-08-28 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
EP2885312A4
(en)
|
2012-08-15 |
2016-01-20 |
Isis Pharmaceuticals Inc |
Method of preparing oligomeric compounds using modified capping protocols
|
LT3421602T
(en)
|
2012-09-06 |
2021-05-25 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
CN111621507A
(en)
|
2012-09-28 |
2020-09-04 |
北卡罗来纳-查佩尔山大学 |
AAV vectors targeting oligodendrocytes
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2013336237A1
(en)
|
2012-10-22 |
2015-06-11 |
Sabag-Rfa Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
AU2013364158A1
(en)
|
2012-12-20 |
2015-07-09 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
CN105658790A
(en)
|
2013-02-21 |
2016-06-08 |
东安大略研究所儿童医院有限公司 |
Vaccine composition
|
BR122020016865B1
(en)
|
2013-03-14 |
2022-12-27 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGONUCLEOTIDE, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE OF SAID COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD)
|
PL2970964T3
(en)
|
2013-03-14 |
2019-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
EP2971142B1
(en)
|
2013-03-14 |
2020-06-24 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression
|
CA2906812A1
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
EA031393B1
(en)
|
2013-05-01 |
2018-12-28 |
Ионис Фармасьютикалз, Инк. |
Compositions and methods for modulating hbv and ttr expression
|
US20160129089A1
(en)
|
2013-06-13 |
2016-05-12 |
Antisense Therapeutics Ltd |
Combination therapy
|
EP3013850B1
(en)
|
2013-06-24 |
2018-07-25 |
Ramot at Tel-Aviv University Ltd. |
Glycogen synthase kinase-3 inhibitors
|
TWI657819B
(en)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
Compositions for modulating tau expression
|
JP2016536343A
(en)
|
2013-09-18 |
2016-11-24 |
ジェームス・クック・ユニバーシティー |
Anti-inflammatory proteins and methods of use
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
CA2931829A1
(en)
|
2013-12-02 |
2015-06-11 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
US9636298B2
(en)
|
2014-01-17 |
2017-05-02 |
Methylgene Inc. |
Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
|
PT3099333T
(en)
|
2014-01-31 |
2020-12-24 |
Univ Temple |
Bag3 as a target for therapy of heart failure
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2015231130C1
(en)
|
2014-03-19 |
2021-12-23 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating Ataxin 2 expression
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
AU2015240761B2
(en)
|
2014-04-01 |
2019-09-12 |
Biogen Ma Inc. |
Compositions for modulating SOD-1 expression
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3647318B1
(en)
|
2014-04-28 |
2021-06-30 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
BR112016022593B1
(en)
|
2014-05-01 |
2022-04-26 |
Ionis Pharmaceuticals, Inc |
Oligomeric compounds, compositions comprising them, and uses thereof
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
ES2812099T3
(en)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating growth hormone receptor expression
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
HRP20220379T1
(en)
|
2014-06-10 |
2022-05-27 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of pompe disease
|
EP3161159B1
(en)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
EP3198012B1
(en)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulating agents
|
CN115040532A
(en)
|
2014-10-10 |
2022-09-13 |
伊黛拉制药有限公司 |
Treatment of cancer using TLR9 agonists and checkpoint inhibitors
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
MX2017006652A
(en)
|
2014-11-21 |
2017-08-21 |
Univ North Carolina Chapel Hill |
Aav vectors targeted to the central nervous system.
|
WO2016081911A2
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
AU2016215124B2
(en)
|
2015-02-06 |
2020-08-06 |
The University Of North Carolina At Chapel Hill |
Optimized human clotting Factor VIII gene expression cassettes and their use
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
DK3283500T3
(en)
|
2015-04-08 |
2020-11-16 |
Univ Chicago |
Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
AU2016259971B2
(en)
|
2015-05-11 |
2021-12-09 |
ProGenis Pty Ltd |
Multiple sclerosis treatment
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
US10590425B2
(en)
|
2015-06-29 |
2020-03-17 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
AU2016298317B2
(en)
|
2015-07-28 |
2021-02-18 |
Caris Science, Inc. |
Targeted oligonucleotides
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
ES2938883T3
(en)
|
2015-11-05 |
2023-04-17 |
Los Angeles Childrens Hospital |
Oligo antisense for use in the treatment of acute myeloid leukemia
|
WO2017079739A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
JOP20200228A1
(en)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
Compositions and methods for decreasing tau expression
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
EA201891601A1
(en)
|
2016-01-10 |
2019-03-29 |
Неоткс Терапьютикс Лтд. |
METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS
|
CN109071625A
(en)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
Smooth mutant and its application method
|
EP3419665A4
(en)
|
2016-02-25 |
2019-10-16 |
The Brigham and Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
JP2019516393A
(en)
|
2016-03-18 |
2019-06-20 |
カリス サイエンス インコーポレイテッド |
Oligonucleotide probes and uses thereof
|
AU2017271579B2
(en)
|
2016-05-25 |
2023-10-19 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
JOP20190065A1
(en)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing tau expression
|
KR20190065341A
(en)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Method of joining oligomeric compounds
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(en)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
WO2018141027A1
(en)
|
2017-02-03 |
2018-08-09 |
The University Of Western Australia |
Novel treatment for neat1 associated disease
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
WO2018195338A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
GB201707501D0
(en)
|
2017-05-10 |
2017-06-21 |
Index Pharmaceuticals Ab |
New therapy 2
|
GB201707503D0
(en)
|
2017-05-10 |
2017-06-21 |
Index Pharmaceuticals Ab |
New Therapy 3
|
EP3665304A4
(en)
|
2017-08-11 |
2021-04-28 |
Agency for Science, Technology and Research |
Method for screening splicing variants or events
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
Modulators of smad7 expression
|
TWI809004B
(en)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
Compounds and methods for reducing snca expression
|
US11597932B2
(en)
|
2017-12-21 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
CN111902537A
(en)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Modulators of DNM2 expression
|
BR112020016001A2
(en)
|
2018-03-02 |
2020-12-15 |
Ionis Pharmaceuticals, Inc. |
IRF4 EXPRESSION MODULATORS
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
CA3095545A1
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
CA3096274A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CN112041440A
(en)
|
2018-04-11 |
2020-12-04 |
Ionis制药公司 |
Modulators of EZH2 expression
|
GB201807312D0
(en)
|
2018-05-03 |
2018-06-20 |
Index Pharmaceuticals Ab |
Formulation
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
CU20200082A7
(en)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF FXI
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
WO2020006267A1
(en)
|
2018-06-27 |
2020-01-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing lrrk2 expression
|
WO2020010059A1
(en)
|
2018-07-02 |
2020-01-09 |
Aptamir Therapeutics, Inc. |
Targeted delivery of therapeutic agents to human adipocytes
|
AR115847A1
(en)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
WO2020048607A1
(en)
|
2018-09-07 |
2020-03-12 |
Université Libre de Bruxelles |
Srsf2 as rna epigenetic factor
|
TW202028222A
(en)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Modulators of foxp3 expression
|
GB201818579D0
(en)
|
2018-11-14 |
2018-12-26 |
Index Pharmaceuticals Ab |
New therapy
|
AU2019380940A1
(en)
|
2018-11-15 |
2021-06-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
KR20210122809A
(en)
|
2019-01-31 |
2021-10-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Regulators of YAP1 expression
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
BR112021015323A2
(en)
|
2019-02-27 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
MALAT1 EXPRESSION MODULATORS
|
WO2020205463A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
KR20220009971A
(en)
|
2019-05-14 |
2022-01-25 |
모나쉬 유니버시티 |
Modulators and regulation of final glycosylation product receptor RNA
|
MX2021013908A
(en)
|
2019-05-15 |
2022-03-11 |
Neotx Therapeutics Ltd |
Cancer treatment.
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
EP4013767A4
(en)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
GB201912191D0
(en)
|
2019-08-24 |
2019-10-09 |
Index Pharmaceuticals Ab |
New therapy
|
WO2021069543A1
(en)
|
2019-10-08 |
2021-04-15 |
Luxembourg Institute Of Health (Lih) |
Inhibitor of dj-1 for use in treating immunoaging
|
SG10201914033YA
(en)
|
2019-12-31 |
2021-07-29 |
Wilmar International Ltd |
Polypeptides with Lipase Activity and Uses Thereof
|
CR20220485A
(en)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
TW202206596A
(en)
|
2020-05-01 |
2022-02-16 |
美商Ionis製藥公司 |
Compounds and methods for modulating atxn1
|
BR112022024206A2
(en)
|
2020-06-29 |
2023-01-03 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS TO MODULATE PLP1
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
GB202018468D0
(en)
|
2020-11-24 |
2021-01-06 |
Index Pharmaceuticals Ab |
New therapy
|
CN117500815A
(en)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
Compounds and methods for reducing IFNAR1 expression
|
EP4147688A1
(en)
|
2021-09-09 |
2023-03-15 |
InDex Pharmaceuticals AB |
Enema formulation
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024044352A1
(en)
|
2022-08-26 |
2024-02-29 |
The General Hospital Corporation |
Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
|